Experimental Oncology

Andrew Shaw

Experimental Oncology
Department of Oncology
University of Alberta
Cross Cancer Institute
11560 University Avenue
Edmonton, Alberta, T6G 1Z2


Dr. Shaw no longer maintains an independent laboratory in Experimental Oncology and is not accepting graduate students or postdoctoral fellows.


Novel regulators of NFkB in breast cancer

The nuclear factor kappa B (NFkB) family of transcription factors are activated in breast cancer where they contribute to tumor progression by inducing genes mediating resistance to apoptosis and promoting cell cycling. NFkB is also activated by cancer therapies incuding radiation and chemotherapy. NFkB is therefore emerging as an important therapeutic target. However, since NFkB plays an essential role in immunity it is preferable to target upstream regulators rather than NFkB itself. We are investigating a putative network of regulators that are better known for their role in immune cells and which are downregulated by estrogen with a view to developing novel therapeutic agents for the control of NFkB in breast cancer. 
Research Interests
Our laboratory is focused on developing therapeutic approaches to opposing tumor progression. We are currently investigating the role of novel regulators of the NFkB family of transcription factors in breast cancer. Loss of estrogen responsiveness in breast cancer correlates inversely with the activation of NFkB signaling pathways influencing resistance to apoptosis, cell cycling, invasiveness and angiogenesis. Consequently NFkB has become an important therapeutic target. We are investigating the role of estrogen-suppressed regulators of NFkB in nonimmune cells with a view to developing novel therapeutic agents. We have observed that several components of this regulatory network localize to the nucleus in breast cancer cells where we hypothesize they regulate NFkB activity by either binding to NFkB or by regulating nuclear organization. Our objective is to identify genes that are uprstrem regulators of NFkB that we can target using adenoviral vectors. 
Our work receives support from Natural Sciences and Engineering Research Council of Canada, and from the Alberta Cancer Foundation. 



Li* N, Shaw* ARE, Zhang N, Mak A, and Li L. Lipid Raft   Proteomics: (*joint first author) Comprehensive Analysis of THP1 Lipid Raft Proteome with SDS-aided in-solution Digestion and Off-line HPLC MALDI MS/MS Sequencing Proteomics 4 (10) 3156-3166 (2004).
Rebecca S. Lam, Andrew R. Shaw and Marek Duszyk (*joint first author).    Membrane Cholesterol Content Modulates Activation of BK Channels in Colonic Epithelia.  Biochim Biophys Acta. 2004: vol 1667(2):241-8